Clinical Trials on Varicose Vein in Hong Kong

Total 22 results

Chinese University of Hong Kong

Completed

EUS-guided Glue Injection for Varices Study

Gastroesophageal Varices

Hong Kong
Hong Kong Children's Hospital

Recruiting

Ultrasound Measurements of Hepatic Vasculatures and Hepatic Doppler Assessment of Healthy Children

Portal Vein | Hepatic Veins | Hepatic Artery | Liver Circulation

Hong Kong
The University of Hong Kong

Unknown

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism

Hong Kong
Southern California Institute for Research and...
Regenesis Biomedical, Inc.

Unknown

Provant Therapy of Venous Stasis Ulcer Trial

Venous Stasis Ulcers

United States
Ripple Therapeutics Pty Ltd
Novotech (Australia) Pty Limited

Active, not recruiting

Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy

Diabetic Macular Oedema | Retinal Vein Occlusion With Macular Oedema

Australia, New Zealand, Hong Kong, Canada
Hanscom, Thomas, M.D.
Genentech, Inc.

Completed

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (RAVEN)

Central Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein Occlusion

United States
Tactile Medical

Terminated

VLU Non-Inferiority Study Comparing a Dual Action Pneumatic Compression Device to Multi-Layer Bandaging

Venous Leg Ulcer

United States
Allergan

Completed

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Macular Edema | Retinal Vein Occlusion

United States, Poland, United Kingdom, Colombia, Spain, Korea, Republic of, Singapore, Brazil, New Zealand, Hong Kong, Italy, Canada, India
Novartis Pharmaceuticals

Completed

Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (Camellia)

Central Retinal Vein Occlusion

China, Taiwan, Hong Kong, Philippines, Vietnam, Indonesia, India
Healthpoint
Smith & Nephew, Inc.

Completed

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

Venous Leg Ulcers

United States, Canada
Novartis Pharmaceuticals

Completed

Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) (Blossom)

Macular Edema Secondary to Branch Retinal Vein Occlusion

China, Taiwan, Hong Kong, Philippines, Vietnam, Indonesia
Healthpoint

Unknown

Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer

Venous Leg Ulcer

United States, Canada
Healthpoint

Completed

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

Venous Leg Ulcers

United States, Canada, Puerto Rico
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)

Central Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)

Macular Edema | Branch Retinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Outlook Therapeutics, Inc.

Completed

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Age-related Macular Degeneration | Diabetic Macular Edema | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | BRVO - Branch Retinal Vein Occlusion

United States
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
Brigham and Women's Hospital
Sanofi

Completed

Discharge ALERT: Quality Improvement Initiative (Discharge)

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism | Prevention | Prophylaxis

United States
Brigham and Women's Hospital
Sanofi

Completed

Multi-Center Human Alert Trial to Prevent DVT and PE

Cancer | Surgery | Deep Vein Thrombosis | Pulmonary Embolism

United States
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more

Clinical Trials on Varicose Vein in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations